Sign in to continue:

Tuesday, March 10th, 2026

Henan Jinma Energy Announces Board Meeting to Approve 2025 Annual Results and Dividend on March 25, 2026 1

Key Points from the Announcement

  • Review and Approval of Audited Annual Results: The Board will consider and, if appropriate, approve the audited annual results for the fiscal year ended 31 December 2025. The results, once approved, will be announced publicly via the websites of The Stock Exchange of Hong Kong Limited and the company. The announcement of annual results is a major event as it provides a comprehensive update on the company’s financial health and operational performance, which can significantly influence investor sentiment and the company’s market valuation.
  • Consideration of Final Dividend: The Board will also deliberate on the payment of a final dividend, if any. The declaration of a dividend is a critical matter for shareholders, as it directly affects the return on their investment. Any decision regarding the final dividend, whether positive or negative, is likely to be price sensitive and could have a material impact on the share value.
  • Other Business Matters: The Board will transact any other business that may arise during the meeting, though specific additional items have not been detailed in the announcement.

Directors Involved in the Decision-Making

The Board is comprised of a mix of executive, non-executive, and independent non-executive directors, ensuring a broad range of oversight and governance. The current composition is as follows:

  • Executive Directors: Mr. XU Huaping and Mr. WANG Lijie
  • Non-Executive Directors: Mr. YIU Chiu Fai (Chairman), Mr. XU Fenglei, Ms. WAN Tingting, and Ms. YE Ting
  • Independent Non-Executive Directors: Mr. SU Jiangang, Mr. ZHANG Xicheng, and Mr. MAN Kwok Leung

Implications for Shareholders and Investors

Investors should closely monitor the outcome of this upcoming Board meeting. The approval and subsequent announcement of the annual results provide vital insights into the company’s financial position and operational progress. In addition, the consideration of a final dividend is particularly noteworthy, as any declaration or omission may directly influence share valuations and investor returns.

Any unexpected outcomes, such as a higher-than-expected dividend, significant changes in financial performance, or new business developments disclosed during the meeting, could result in considerable share price movement. Conversely, disappointing financial results or the absence of a final dividend could negatively affect investor confidence and the company’s market value.

Next Steps

The results of the Board meeting, including any decisions on the annual results and dividend, are expected to be published soon after the meeting date. Investors are advised to stay alert for further announcements from Henan Jinma Energy Company Limited.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions. The author and publisher are not responsible for any losses resulting from reliance on this information.

View JINMA ENERGY Historical chart here



Yixin Group 2025 Annual Results: Strong Growth in Automotive Finance, SaaS, and International Expansion

Yixin Group 2025 Annual Results: Key Highlights and Investor Insights Yixin Group 2025 Annual Results: Key Highlights and Investor Insights Robust Financial Performance Amid Complex Market Conditions Revenue: Yixin Group delivered total revenue of...

Triumph New Energy Company Limited Announces Board Meeting to Approve 2025 Annual Results

Triumph New Energy Company Limited Announces Upcoming Board Meeting to Approve FY2025 Annual Results Triumph New Energy Company Limited Announces Upcoming Board Meeting to Approve FY2025 Annual Results Triumph New Energy Company Limited (Stock...

Ruxolitinib Phosphate Cream for Atopic Dermatitis Granted Priority Review in China—China Medical System Announces NDA Acceptance and Business Update 1

China Medical System Announces Key Regulatory Milestone for Ruxolitinib Phosphate Cream in Atopic Dermatitis China Medical System’s Dermavon Achieves Major Regulatory Milestone: Ruxolitinib Phosphate Cream NDA for Atopic Dermatitis Accepted and Granted Priority Review...

   Ad